Pertussis Completed Phase 3 Trials for Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)

Also known as: Whooping cough due to Bordetella pertussis / Whooping Cough / Whooping cough due to bordetella pertussis (B. pertussis)

IndicationStatusPhase
DBCOND0014696 (Pertussis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00148941Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV VaccinesPrevention
NCT00835237Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.Prevention
NCT01309646Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccinePrevention
NCT02858440A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in RussiaPrevention
NCT00385255Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsPrevention
NCT00508261Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each VaccinePrevention
NCT00346073Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsPrevention
NCT00412854Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.Prevention
NCT00696423Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in ChildrenPrevention
NCT00964028Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)Prevention
NCT00871000Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.Prevention
NCT01086423Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ VaccinePrevention
NCT00432042Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)Prevention
NCT01457508Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyPrevention
NCT00255047Safety and Immune Response of Different Pediatric Combination Vaccines.Prevention
NCT00258895Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®Prevention
NCT00287092Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsPrevention
NCT00343421Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersPrevention
NCT00366366To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV VaccinesPrevention
NCT00406562Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.Prevention
NCT00404651Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy InfantsPrevention
NCT00401531Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai InfantsPrevention
NCT00452686Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT VaccinePrevention
NCT00467519Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of AgePrevention
NCT00654901Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™Prevention
NCT00772928Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™Prevention
NCT00831753Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsPrevention
NCT01040052A Study to Assess the Safety of Adacel® VaccinePrevention
NCT01277705Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®Prevention
NCT01346293Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of AgePrevention
NCT01457560Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccinePrevention
NCT01993173Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.Prevention
NCT02089347Study of SP306 Given Intramuscularly Compared to DT BIK® Given Subcutaneously in Japanese Adolescents 11 - 12 Years OldPrevention